SK1087. Ningalin B Analogs Employable for Reversing Multidrug Resistance

Summary of Invention

The ningalins are a class of recently identified marine natural products. These compounds have been found to inhibit P-glycoprotein, lack intrinsic cytotoxic activity, and reverse MDR in vitro. More recent studies show that certain ningalin analogs have enormous potency in MDR-reversal and collateral efficacy.

Advantages

• Concise total synthesis of ningalin B and analogs has been worked out.
• Analogs have been characterized against drug-resistant cell lines, and profound reversal of anticancer multidrug reversal demonstrated.
• Analogs have also been tested in mouse xenograft models.

Areas of Application

Therapeutic drug.

Stage of Development

Further animal studies required.

Lead Inventor

Dr. Dale L. Boger of The Scripps Research Institute;
Sloan-Kettering holds marketing rights.

Patent Information

• US patent prosecution ongoing.
• PCT application published as WO 01/64635.
• Patent prosecution ongoing in Europe, Canada, and Japan.

References

Chou TC, et al. Cancer Chemother. Pharmacol, 2005 Oct;56(4):379-90

Related Inventions

• SK 655. N-acetyl ardeemin and analogues, method of preparation and uses thereof.
• SK 1020. Immunosuppressive ningalin compounds.

Contact Information

Julia Calonge, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: calongej@mskcc.org